On April 3, 2024 Pluristyx, a leading provider of tools, technologies, and services for cellular therapies, reported the release of its proprietary cryopreservation medium solution, PluriFreeze (Press release, panCELLa, APR 3, 2024, View Source [SID1234641744]). Immediately available in a Research Use Only (RUO) formulation with a Good Manufacturing Practice (GMP) version on the horizon, PluriFreeze constitutes a further addition to Pluristyx’s panCELLa Platform for iPSC therapeutic development, with broad applicability for other sensitive cell types.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PluriFreeze is an innovative solution designed to support cell metabolism and ease pluripotent stem and other energetically active cells to and from the frozen state to enhance post-thaw viability and function. In comparison to other commercially available cryo-media, PluriFreeze offers significant benefits for cell therapy development that include an entirely synthetic and Animal-Origin Free (AOF) composition, low viscosity for automation and large-scale cell production, and a companion DMSO-free PluriPrep wash solution to enable extended processing times. In addition, PluriFreeze is entirely formulated with components Generally Recognized As Safe (GRAS) by the US Federal Food, Drug, and Cosmetic Act to ensure a consistently safe and reliable cryopreservation solution.
Ben Fryer, CEO of Pluristyx, stated, "Our goal as an organization is to be a problem-solving partner for our customers, and one of the long-standing challenges for cell therapy developers has been the availability of high-performing, scalable, and cost-effective cryopreservation formulations. The launch of PluriFreeze represents a significant step forward in our commitment to providing comprehensive solutions for iPSCs with an entirely synthetic and AOF workflow. The strong compatibility of PluriFreze with our PluriBank, clinical-grade, pre-edited iPSCs, allows us to offer an integrated approach to our customers. Furthermore, the ability to complement PluriFreeze with our existing cryo-development services enables us to optimize our customers’ entire cryopreservation workflow with an eye toward the commercialization and the clinic. We invite our customers and collaborators to test PluriFreeze today to simplify their cryopreservation workflows."